ES2608816T3 - Composición farmacéutica oral de desmopresina - Google Patents

Composición farmacéutica oral de desmopresina Download PDF

Info

Publication number
ES2608816T3
ES2608816T3 ES08805367.3T ES08805367T ES2608816T3 ES 2608816 T3 ES2608816 T3 ES 2608816T3 ES 08805367 T ES08805367 T ES 08805367T ES 2608816 T3 ES2608816 T3 ES 2608816T3
Authority
ES
Spain
Prior art keywords
pharmaceutical composition
oral pharmaceutical
desmopressin
desmopressin oral
hemorrhages
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08805367.3T
Other languages
English (en)
Inventor
Nuria Carbajal Navarro
Antonio BOIX MONTAÑES
Carlos Nieto Abad
Antonio PARENTE DUEÑA
Ricard Mis Vizcaino
Cesar GARCÍA PLUMED
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratorio Reig Jofre SA
GP Pharm SA
Original Assignee
Laboratorio Reig Jofre SA
GP Pharm SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorio Reig Jofre SA, GP Pharm SA filed Critical Laboratorio Reig Jofre SA
Application granted granted Critical
Publication of ES2608816T3 publication Critical patent/ES2608816T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composición farmacéutica oral y líquida de desmopresina, y su usopara el tratamiento de la diabetes insípida central, enuresis primaria nocturna, hemorragias en pacientes con Hemofilia A, con enfermedad de von Willebrand-Jürgens y hemorragias post-quirúrgicas.

Description

imagen1
imagen2
imagen3
imagen4
imagen5

Claims (1)

  1. imagen1
ES08805367.3T 2007-08-06 2008-08-01 Composición farmacéutica oral de desmopresina Active ES2608816T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES200702215A ES2319054B1 (es) 2007-08-06 2007-08-06 Composicion farmaceutica oral de desmopresina.
ES200702215 2007-08-06
PCT/ES2008/000539 WO2009027561A2 (es) 2007-08-06 2008-08-01 Composición farmacéutica oral de desmopresina

Publications (1)

Publication Number Publication Date
ES2608816T3 true ES2608816T3 (es) 2017-04-17

Family

ID=40032884

Family Applications (2)

Application Number Title Priority Date Filing Date
ES200702215A Active ES2319054B1 (es) 2007-08-06 2007-08-06 Composicion farmaceutica oral de desmopresina.
ES08805367.3T Active ES2608816T3 (es) 2007-08-06 2008-08-01 Composición farmacéutica oral de desmopresina

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES200702215A Active ES2319054B1 (es) 2007-08-06 2007-08-06 Composicion farmaceutica oral de desmopresina.

Country Status (18)

Country Link
US (1) US8993521B2 (es)
EP (1) EP2174652B1 (es)
JP (1) JP5626682B2 (es)
CN (2) CN106265494A (es)
AR (1) AR068337A1 (es)
BR (1) BRPI0814835B8 (es)
CY (1) CY1118459T1 (es)
DK (1) DK2174652T3 (es)
ES (2) ES2319054B1 (es)
HR (1) HRP20161676T1 (es)
HU (1) HUE032667T2 (es)
LT (1) LT2174652T (es)
MX (1) MX2010001456A (es)
PL (1) PL2174652T3 (es)
PT (1) PT2174652T (es)
RU (1) RU2474414C2 (es)
SI (1) SI2174652T1 (es)
WO (1) WO2009027561A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3400B1 (ar) * 2010-09-30 2019-10-20 Ferring Bv مركب صيدلاني من كاربيتوسين
WO2024211393A2 (en) * 2023-04-04 2024-10-10 Tulex Pharmaceuticals Inc. Desmopressin oral compositions

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8306367L (sv) 1983-11-18 1985-05-19 Ferring Ab Antidiuretiskt verkande farmaceutiskt preparat
DE69010518T2 (de) 1989-01-30 1994-11-03 Corint Ltd Wässerige Desmopressin-CMC enthaltende Arzneizubereitung.
JP2653255B2 (ja) * 1990-02-13 1997-09-17 武田薬品工業株式会社 長期徐放型マイクロカプセル
AU653026B2 (en) 1991-06-07 1994-09-15 Teikoku Seiyaku Kabushiki Kaisha Physiologically active polypeptide-containing pharmaceutical composition
US5298256A (en) 1992-04-28 1994-03-29 Corint, Ltd. Desmopressin buccal patch composition
IT1255460B (it) 1992-07-28 1995-11-02 Poli Ind Chimica Spa Composizioni farmaceutiche in forma di microemulsioni o di dispersioni liposomiali bioadesive per la somministrazione transmucosale di sostanze peptidiche e di proteine farmacologicamente attive
SE9300937L (sv) 1993-03-19 1994-09-20 Anne Fjellestad Paulsen Komposition för oral administrering av peptider
US5482931A (en) * 1993-06-29 1996-01-09 Ferring Ab Stabilized pharmaceutical peptide compositions
SE9400918L (sv) 1994-03-18 1995-09-19 Anne Fjellstad Paulsen Stabiliserad komposition för oral administrering av peptider
US5763398A (en) 1996-06-20 1998-06-09 Ferring B.V. Nasal administration of desmopressin
US20030095926A1 (en) 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract
IL142808A0 (en) * 1998-11-02 2002-03-10 Alza Corp Electrotransport device including a compatible antimicrobial agent
US6894026B1 (en) 2000-01-11 2005-05-17 Atossa Healthcare, Inc. Long-acting oxytocin analogues for the treatment and prevention of breast cancer and psychiatric disorders
EP1121935B1 (en) * 2000-02-04 2008-08-13 Patents Exploitation Company B.V. Pharmaceutical composition containing a small or medium size peptide
AT409081B (de) * 2000-02-16 2002-05-27 Gebro Pharma Gmbh Stabile, nasal, oral oder sublingual anwendbare pharmazeutische zubereitung
GB0210397D0 (en) 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
WO2003097080A1 (en) * 2002-05-15 2003-11-27 Sun Pharmaceutical Industries Limited A stable aqueous composition of a peptide
ITMI20021684A1 (it) 2002-07-29 2004-01-29 Therapicon Srl Composizione farmaceutica di peptide nasale
KR20050107401A (ko) * 2003-01-24 2005-11-11 마글레 홀딩 아베 점막투과 전달용 조성물 재료
ES2236640T3 (es) 2003-04-30 2005-07-16 Ferring B.V. Forma posologica de la desmopresina.
DE60301351T2 (de) 2003-07-25 2006-01-19 Ferring B.V. Pharmazeutische Desmopressin-Zubereitung als feste Darreichungsform und Methode zu ihrer Herstellung
EP2322195A2 (en) 2003-11-10 2011-05-18 Reprise Biopharmaceutics, LLC Pharmaceutical compositions including low dosages of desmopressin
GB0406048D0 (en) 2004-03-18 2004-04-21 Ardana Bioscience Ltd Drug formulations
US20050244502A1 (en) 2004-04-28 2005-11-03 Mathias Neil R Composition for enhancing absorption of a drug and method

Also Published As

Publication number Publication date
US8993521B2 (en) 2015-03-31
LT2174652T (lt) 2017-02-27
WO2009027561A3 (es) 2009-07-16
CN106265494A (zh) 2017-01-04
ES2319054A1 (es) 2009-05-01
PT2174652T (pt) 2016-12-23
PL2174652T3 (pl) 2017-06-30
EP2174652B1 (en) 2016-10-05
JP2010535745A (ja) 2010-11-25
RU2010105031A (ru) 2011-09-20
ES2319054B1 (es) 2010-02-12
HUE032667T2 (en) 2017-10-30
BRPI0814835B1 (pt) 2020-10-27
MX2010001456A (es) 2010-06-02
AR068337A1 (es) 2009-11-11
CN101808621A (zh) 2010-08-18
CY1118459T1 (el) 2017-07-12
DK2174652T3 (en) 2017-01-23
SI2174652T1 (sl) 2017-04-26
EP2174652A2 (en) 2010-04-14
WO2009027561A2 (es) 2009-03-05
HRP20161676T1 (hr) 2017-02-24
JP5626682B2 (ja) 2014-11-19
BRPI0814835A2 (pt) 2015-03-31
BRPI0814835B8 (pt) 2021-05-25
US20110251123A1 (en) 2011-10-13
RU2474414C2 (ru) 2013-02-10

Similar Documents

Publication Publication Date Title
ES2524345T3 (es) Composición farmacéutica oral
ES2534191T3 (es) Composición farmacéutica que comprende un agonista de GLP-1, una insulina y metionina
ES2502472T3 (es) Composición adhesiva para su uso en un inmunosensor
CL2007001724A1 (es) Uso de un estrogeno para el tratamiento de enfermedades, condiciones o sintomas asociados con niveles deficientes de estrogenos en una mujer; composicion farmaceutica que comprende unidades de dosificacion diarias de hemidrato de estradiol > 0,75 y 1
EA201100958A1 (ru) Фармацевтическая пероральная дозированная лекарственная форма на основе ингибиторов dpp iv
ES2515168T3 (es) Detección y tratamiento de la esquizofrenia
CL2008002111A1 (es) Compuestos derivados de piridona, agonistas del receptor acoplado a proteina g gpr119; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como diabetes, sindrome metabolico, cancer, entre otras.
CL2008001126A1 (es) Compuestos derivados de pirimidinona condensada con heterociclos; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como diabetes, sindrome metabolico y obesidad.
EA201401028A1 (ru) Фармацевтическая композиция, содержащая эмпаглифлозин и лекарственное средство от ожирения
CL2007001902A1 (es) Compuestos derivados de piridina sustituidas; composicion farmaceutica; y uso en el tratamiento de un trastorno de agregacion de plaquetas.
CL2007002967A1 (es) Forma cristalina a del compuesto 4-[3-(4-ciclopropancarbonil-piperazin-1-carbonil)-4-fluoro-bencil]-2h-ftalazin-1-ona; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de un
CL2007002018A1 (es) Compuestos derivados de isoxazolinas sustituidas; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto para el tratamiento de una enfermedad causada por un aumento en la proliferacion celular.
CL2007003262A1 (es) Compuestos derivados de 1,4-benzotiepina-1,1-dioxido; composicion farmaceutica; y su uso para el tratamiento de trastornos del metabolismo de lipidos, hiperlipidemia, resistencia a la insulina, diabetes y trastornos del snc, entre otras enfermedades.
CL2008000791A1 (es) Compuestos derivados de 2-amino-5-(4-difluorometoxi-fenil)-5-fenil-imidazolidin-4-ona; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de una enfermedad asociada con la actividad bace excesiva, tales como enferm
BRPI0815577A2 (pt) Peptídeo foxm1 e agente medicinal compreendendo o mesmo.
DE602005007873D1 (de) Röntgensichtbare arzneimittelabgabevorrichtung
CY1117603T1 (el) Η λιξισενατιδη ως προσθετο στη μετφορμινη στην θεραπευτικη αγωγη του διαβητη τυπου 2
WO2006041878A3 (en) Primary examiner
CL2007002875A1 (es) Composicion farmaceutica recubierta por una pelicula que comprende capecitabina y al menos un disgregante, util en el tratamiento del cancer para pacientes que tienen dificultad para tragar las formas de dosificacion solidas orales.
CL2008001820A1 (es) Compuestos derivados de aril-isoxasol-imidazol; procedimiento de preparacion; composicion farmaceutica que los contiene; y uso en la preparacion de medicamentos utiles en el tratamiento de trastornos cognitivos y enfermedades relacionadas con alzheimer.
CO6771406A2 (es) Una composición combinada
ES2482168T3 (es) Uso de opioides del grupo de la metadona para el tratamiento de pacientes con cáncer resistente
AR086395A1 (es) Envase para el tratamiento de patologias
UY30461A1 (es) Composicion farmacéutica para la anticoncepcion y para reducir el riesgo de malformaciones congénitas.
ES2608816T3 (es) Composición farmacéutica oral de desmopresina